B · Normal
[Zejing Pharmaceutical: The pivotal clinical trial of ZG006 reaches the preset primary endpoint] On November 18th, Zejing Pharmaceutical (688266.SH) announced that the interim analysis of the pivotal clinical trial of the company's independently developed Class 1 new drug ZG006 for injection as a single agent in the treatment of advanced small cell lung cancer reached the preset primary endpoint. After the independent data monitoring committee reviews and determines that the test meets the standards, the company will submit a Pre-BLA communication application to the Drug Evaluation Center of the State Food and Drug Administration to speed up the marketing process. This matter has no significant impact on recent performance.
A-share announcement express 🕐 2026-11-18 17:39

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet